Rapt Therapeutics, INC Form 4 insider transactions
RAPT Therapeutics CEO, Brian Russell Wong, was granted 1,746,000 stock options on January 30, 2025, according to a recent SEC filing.
Column Group II, LP and Ponoi Capital, LP exchanged RAPT Therapeutics shares for pre-funded warrants on December 23, 2024.
Several key insiders at RAPT Therapeutics, including Column Group II, LP and Ponoi Capital, LP, exchanged common stock for pre-funded warrants on December 23, 2024.
RAPT Therapeutics' Chief Financial Officer, Rodney Young, amended several employee stock options, resulting in the cancellation of old options and the grant of new ones with a lower exercise price.
RAPT Therapeutics CEO, Brian Russell Wong, amended several employee stock options on November 13, 2024, resulting in the cancellation of old options and the grant of new ones with a lower exercise price.
RAPT Therapeutics' Chief Medical Officer, William Ho, amended several employee stock options on November 13, 2024, resulting in the cancellation of old options and the grant of new replacement options.
RAPT Therapeutics' Chief Scientific Officer, Dirk G. Brockstedt, amended several employee stock options, resulting in the cancellation of old options and the grant of new ones with a lower exercise price.
Wendye Robbins, a director at RAPT Therapeutics, acquired stock options for 36,490 shares of common stock on May 22, 2024.
Director William Rieflin acquired stock options in RAPT Therapeutics, Inc.
Lori Lyons-Williams, a director of RAPT Therapeutics, acquired stock options for 36,490 shares of common stock on May 22, 2024.
Director Linda Kozick acquired stock options in RAPT Therapeutics, Inc. on May 22, 2024.
Mary Ann Gray, a director of RAPT Therapeutics, acquired 36,490 stock options on May 22, 2024, exercisable for common stock.
Michael F. Giordano, a director of RAPT Therapeutics, acquired stock options on May 22, 2024.
Wendye Robbins, a director at RAPT Therapeutics, acquired stock options in lieu of a cash retainer, signaling continued alignment with the company's long-term performance.
Director Mary Ann Gray acquired stock options in RAPT Therapeutics in lieu of a cash retainer for board service.
Director William J.L. Rieflin acquired stock options in RAPT Therapeutics, Inc. in lieu of cash retainers.